{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:36:13Z","timestamp":1789475773938,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13023-017-0733-y","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T12:05:34Z","timestamp":1515413134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications"],"prefix":"10.1186","volume":"13","author":[{"given":"G\u00e9-Ann","family":"Kuiper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga L. M.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline J.","family":"Langereis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits A.","family":"Wijburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,8]]},"reference":[{"key":"733_CR1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ymgme.2016.07.009","volume":"119","author":"EC Lisi","year":"2016","unstructured":"Lisi EC, Gillespie S, Laney D, Ali N. Patients\u2019 perspectives on newborn screening for later-onset lysosomal storage diseases. Mol Genet Metab. 2016;119:109\u201314.","journal-title":"Mol Genet Metab"},{"key":"733_CR2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ymgme.2012.08.008","volume":"107","author":"MH de Ru","year":"2012","unstructured":"de Ru MH, Bouwman MG, Wijburg FA, van Zwieten MCB. Experiences of parents and patients with the timing of Mucopolysaccharidosis type I (MPS I) diagnoses and its relevance to the ethical debate on newborn screening. Mol Genet Metab. 2012;107:501\u20137.","journal-title":"Mol Genet Metab"},{"key":"733_CR3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ymgmr.2016.07.006","volume":"8","author":"S Bruni","year":"2016","unstructured":"Bruni S, Lavery C, Broomfield A. The diagnostic journey of patients with mucopolysaccharidosis I: a real-world survey of patient and physician experiences. Mol Genet Metab Reports. 2016;8:67\u201373.","journal-title":"Mol Genet Metab Reports"},{"key":"733_CR4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13023-017-0622-4","volume":"12","author":"Y Zurynski","year":"2017","unstructured":"Zurynski Y, Deverell M, Dalkeith T, Johnson S, Christodoulou J, Leonard H, et al. Australian children living with rare diseases: experiences of diagnosis and perceived consequences of diagnostic delays. Orphanet J Rare Dis. 2017;12:68.","journal-title":"Orphanet J Rare Dis"},{"key":"733_CR5","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","volume":"125","author":"M Aldenhoven","year":"2015","unstructured":"Aldenhoven M, Wynn RF, Orchard PJ, O\u2019Meara A, Veys P, Fischer A, et al. Long-term outcome of hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015;125:2164\u201372.","journal-title":"Blood"},{"key":"733_CR6","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1542\/peds.2009-1728","volume":"125","author":"O Gabrielli","year":"2010","unstructured":"Gabrielli O, Clarke LA, Bruni S, Coppa GV. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics. 2010;125:e183\u20137.","journal-title":"Pediatrics"},{"key":"733_CR7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ymgme.2013.04.023","volume":"109","author":"S Laraway","year":"2013","unstructured":"Laraway S, Breen C, Mercer J, Jones S, Wraith JE. Does early use of enzyme replacement therapy alter the natural history of mucopolysaccharidosis I? Experience in three siblings. Mol Genet Metab. 2013;109:315\u20136.","journal-title":"Mol Genet Metab"},{"key":"733_CR8","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/adc.2007.134940","volume":"93","author":"Y Zurynski","year":"2008","unstructured":"Zurynski Y, Frith K, Leonard H, Elliott E. Rare childhood diseases: how should we respond? Arch Dis Child. 2008;93:1071\u20134.","journal-title":"Arch Dis Child"},{"key":"733_CR9","first-page":"2836","volume":"295","author":"T Hampton","year":"2006","unstructured":"Hampton T. Rare disease research gets boost. JAMA. 2006;295:2836\u20138.","journal-title":"JAMA"},{"key":"733_CR10","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0140-6736(08)60872-7","volume":"371","author":"A Schieppati","year":"2008","unstructured":"Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008;371:2039\u201341.","journal-title":"Lancet"},{"key":"733_CR11","volume-title":"Metab Mol Bases Inherit Dis","author":"EF Neufeld","year":"2014","unstructured":"Neufeld EF, Muenzer J. The Mucopolysaccharidoses. In: Valle D, Beaudet A, Vogelstein B, et al., editors. Metab Mol Bases Inherit Dis. New York: McGraw-Hill; 2014."},{"key":"733_CR12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10545-008-0838-5","volume":"31","author":"MJ Valstar","year":"2008","unstructured":"Valstar MJ, Ruijter GJG, van Diggelen OP, Poorthuis BJ, Wijburg FA. Sanfilippo syndrome: a mini-review. J Inherit Metab Dis. 2008;31:240\u201352.","journal-title":"J Inherit Metab Dis"},{"key":"733_CR13","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jpeds.2015.11.079","volume":"170","author":"EG Shapiro","year":"2016","unstructured":"Shapiro EG, Nestrasil I, Delaney KA, Rudser K, Kovac V, Nair N, et al. A prospective natural history study of Mucopolysaccharidosis type IIIA. J Pediatr. 2016;170:278\u2013287e4.","journal-title":"J Pediatr"},{"key":"733_CR14","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1080\/08035250510031584","volume":"94","author":"S Vijay","year":"2005","unstructured":"Vijay S, Wraith JE. Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr. 2005;94:872\u20137.","journal-title":"Acta Paediatr"},{"key":"733_CR15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1651-2227.1995.tb13640.x","volume":"84","author":"M Cleary","year":"1995","unstructured":"Cleary M, Wraith JE. The presenting features of mucopolysaccharidosis type IH (hurler syndrome). Acta Paediatr. 1995;84:337\u20139.","journal-title":"Acta Paediatr"},{"issue":"Suppl 5","key":"733_CR16","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","volume":"50","author":"J Muenzer","year":"2011","unstructured":"Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology. 2011;50(Suppl 5):v4\u201312.","journal-title":"Rheumatology"},{"key":"733_CR17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ymgme.2007.01.011","volume":"91","author":"GM Pastores","year":"2007","unstructured":"Pastores GM, Arn P, Beck M, Clarke JTR, Guffon N, Kaplan P, et al. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis type I. Mol Genet Metab. 2007;91:37\u201347.","journal-title":"Mol Genet Metab"},{"key":"733_CR18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00431-011-1644-x","volume":"171","author":"K D\u2019Aco","year":"2012","unstructured":"D\u2019Aco K, Underhill L, Rangachari L, Arn P, Cox GF, Giugliani R, et al. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I registry. Eur J Pediatr. 2012;171:911\u20139.","journal-title":"Eur J Pediatr"},{"key":"733_CR19","first-page":"759","volume":"16","author":"M Beck","year":"2014","unstructured":"Beck M, Arn P, Giugliani R, Muenzer J, Okuyama T, Taylor J, et al. The natural history of MPS I: global perspectives from the MPS I registry. Genet Med American College of Medical Genetics and Genomics. 2014;16:759\u201365.","journal-title":"Genet Med American College of Medical Genetics and Genomics"},{"key":"733_CR20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10545-010-9113-7","volume":"33","author":"JA Thomas","year":"2010","unstructured":"Thomas JA, Beck M, Clarke JTR, Cox GF. Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis i. J Inherit Metab Dis. 2010;33:421\u20137.","journal-title":"J Inherit Metab Dis"},{"key":"733_CR21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","volume":"123","author":"J Muenzer","year":"2009","unstructured":"Muenzer J, Wraith JE, Clarke LA. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009;123:19\u201329.","journal-title":"Pediatrics"},{"key":"733_CR22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1750-1172-6-55","volume":"6","author":"MH de Ru","year":"2011","unstructured":"de Ru MH, Boelens JJ, Das AM, Jones SA, van der Lee JH, Mahlaoui N, et al. Enzyme replacement therapy and\/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis. 2011;6:55.","journal-title":"Orphanet J Rare Dis."},{"key":"733_CR23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13023-015-0344-4","volume":"10","author":"NA Al-Sannaa","year":"2015","unstructured":"Al-Sannaa NA, Bay L, Barbouth DS, Benhayoun Y, Goizet C, Guelbert N, et al. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships. Orphanet J Rare Dis Orphanet Journal of Rare Diseases. 2015;10:131.","journal-title":"Orphanet J Rare Dis Orphanet Journal of Rare Diseases"},{"key":"733_CR24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12881-016-0284-4","volume":"17","author":"O Gabrielli","year":"2016","unstructured":"Gabrielli O, Clarke LA, Ficcadenti A, Santoro L, Zampini L, Volpi N, et al. 12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment. BMC Med Genet BMC Medical Genetics. 2016;17:19.","journal-title":"BMC Med Genet BMC Medical Genetics"},{"key":"733_CR25","doi-asserted-by":"crossref","first-page":"e1255","DOI":"10.1542\/peds.2007-0282","volume":"120","author":"A Meyer","year":"2007","unstructured":"Meyer A, Kossow K, Gal A, M\u00fchlhausen C, Ullrich K, Braulke T, et al. Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type a). Pediatrics. American Academy of Pediatrics. 2007;120:e1255\u201361.","journal-title":"Pediatrics"},{"key":"733_CR26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ajmg.a.33779","volume":"155A","author":"B H\u00e9ron","year":"2011","unstructured":"H\u00e9ron B, Mikaeloff Y, Froissart R, Caridade G, Maire I, Caillaud C, et al. Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece. Am J Med Genet A. 2011;155A:58\u201368.","journal-title":"Am J Med Genet A"},{"key":"733_CR27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/1750-1172-8-189","volume":"8","author":"V Delgadillo","year":"2013","unstructured":"Delgadillo V, O\u2019Callaghan M del M, Gort L, Coll MJ, Pineda M. Natural history of Sanfilippo syndrome in Spain. Orphanet J Rare Dis. 2013;8:189.","journal-title":"Orphanet J Rare Dis"},{"key":"733_CR28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s10545-014-9718-3","volume":"37","author":"CEM Hollak","year":"2014","unstructured":"Hollak CEM, Wijburg FA. Treatment of lysosomal storage disorders: successes and challenges. J Inherit Metab Dis. 2014;37:587\u201398.","journal-title":"J Inherit Metab Dis"},{"key":"733_CR29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev-med-122313-085916","volume":"66","author":"G Parenti","year":"2015","unstructured":"Parenti G, Andria G, Ballabio A. Lysosomal storage diseases: from Pathophysiology to therapy. Annu Rev Med. 2015;66:471\u201386.","journal-title":"Annu Rev Med"},{"key":"733_CR30","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s10545-010-9199-y","volume":"33","author":"MJ Valstar","year":"2010","unstructured":"Valstar MJ, Bruggenwirth HT, Olmer R, Wevers RA, Verheijen FW, Poorthuis BJ, et al. Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype. J Inherit Metab Dis. 2010;33:759\u201367.","journal-title":"J Inherit Metab Dis"},{"key":"733_CR31","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/ana.22092","volume":"68","author":"MJ Valstar","year":"2010","unstructured":"Valstar MJ, Neijs S, Bruggenwirth HT, Olmer R, Ruijter GJG, Wevers RA, et al. Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol. 2010;68:876\u201387.","journal-title":"Ann Neurol"},{"key":"733_CR32","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/ajmg.a.36110","volume":"161","author":"PS Kishnani","year":"2013","unstructured":"Kishnani PS, Amartino HM, Lindberg C, Miller TM, Wilson A, Keutzer J. Timing of diagnosis of patients with pompe disease: data from the pompe registry. Am J Med Genet Part A. 2013;161:2431\u201343.","journal-title":"Am J Med Genet Part A."},{"key":"733_CR33","doi-asserted-by":"crossref","unstructured":"N\u00f8rmark MB, LA Kjaer N. Prevalence of Mucopolysaccharidosis types I, II, and VI in the pediatric and adult population with carpal tunnel syndrome (CTS). Retrospective and prospective analysis of patients treated for CTS. JIMD Rep. 2017; Epub ahead","DOI":"10.1007\/8904_2016_32"},{"key":"733_CR34","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ymgme.2014.01.011","volume":"111","author":"CDM Van Karnebeek","year":"2014","unstructured":"Van Karnebeek CDM, Shevell M, Zschocke J, Moeschler JB, Stockler S. The metabolic evaluation of the child with an intellectual developmental disorder: diagnostic algorithm for identification of treatable causes and new digital resource. Mol Genet Metab. 2014;111:428\u201338.","journal-title":"Mol Genet Metab"},{"key":"733_CR35","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.21435","volume":"64","author":"HM Engbers","year":"2008","unstructured":"Engbers HM, Berger R, Van Hasselt P, De Koning T, De Sain-Van Der Velden MGM, Kroes HY, et al. Yield of additional metabolic studies in neurodevelopmental disorders. Ann Neurol. 2008;64:212\u20137.","journal-title":"Ann Neurol"},{"key":"733_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2015.03.001","volume":"115","author":"B Sayson","year":"2015","unstructured":"Sayson B, Popurs MAM, Lafek M, Berkow R, Stockler-Ipsiroglu S, van Karnebeek CDM. Retrospective analysis supports algorithm as efficient diagnostic approach to treatable intellectual developmental disabilities. Mol Genet Metab. 2015;115:1\u20139.","journal-title":"Mol Genet Metab"},{"key":"733_CR37","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1136\/adc.2005.072025","volume":"90","author":"MA Cleary","year":"2005","unstructured":"Cleary MA, Green A. Developmental delay: when to suspect and how to investigate for an inborn error of metabolism. Arch Dis Child. 2005;90:1128\u201332.","journal-title":"Arch Dis Child"},{"key":"733_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2196\/jmir.6663","volume":"19","author":"A Cahan","year":"2017","unstructured":"Cahan A, Cimino JJ. A learning health care system using computer-aided diagnosis. J Med Internet Res. 2017;19:1\u201312.","journal-title":"J Med Internet Res"},{"key":"733_CR39","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.clinthera.2015.12.001","volume":"38","author":"Y Chen","year":"2016","unstructured":"Chen Y, Argentinis E, Weber G. IBM Watson: how cognitive computing can be applied to big data challenges in life sciences research. Clin Ther. 2016;38:688\u2013701.","journal-title":"Clin Ther"},{"key":"733_CR40","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/ajmg.a.37672","volume":"170","author":"KW Gripp","year":"2016","unstructured":"Gripp KW, Baker L, Telegrafi A, Monaghan KG. The role of objective facial analysis using FDNA in making diagnoses following whole exome analysis. Report of two patients with mutations in the BAF complex genes. Am J Med Genet Part A. 2016;170:1754\u201362.","journal-title":"Am J Med Genet Part A"},{"key":"733_CR41","unstructured":"Wilson JMG, Jungner G. Principles and practice of screening for disease. World Heal Organ. 1968;163"},{"key":"733_CR42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/ijns3020006","volume":"3","author":"P Schielen","year":"2017","unstructured":"Schielen P, Kemper E, Gelb M. Newborn screening for Lysosomal storage diseases: a concise review of the literature on screening methods. Therapeutic Possibilities and Regional Programs Int J Neonatal Screen. 2017;3:6.","journal-title":"Therapeutic Possibilities and Regional Programs Int J Neonatal Screen"},{"key":"733_CR43","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/GIM.0b013e318211a7e1","volume":"13","author":"RY Wang","year":"2011","unstructured":"Wang RY, Bodamer OA, Watson MS, Wilcox WR. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med The American College of Medical Genetics. 2011;13:457\u201384.","journal-title":"Genet Med"},{"key":"733_CR44","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13023-017-0662-9","volume":"12","author":"R Parini","year":"2017","unstructured":"Parini R, Deodato F, Di Rocco M, Lanino E, Locatelli F, Messina C, et al. Open issues in Mucopolysaccharidosis type I-hurler. Orphanet J Rare Dis. Orphanet Journal of Rare Diseases. 2017;12:112.","journal-title":"Orphanet J Rare Dis."},{"key":"733_CR45","first-page":"1","volume":"2017","author":"BK Burton","year":"2017","unstructured":"Burton BK, Charrow J, Hoganson GE, Waggoner D, Tinkle B, Braddock SR, et al. Newborn screening for Lysosomal storage disorders in Illinois: the initial 15-month experience. J Pediatr. 2017;2017:1\u20136.","journal-title":"J Pediatr"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-017-0733-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T10:18:20Z","timestamp":1719742700000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-017-0733-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,8]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["733"],"URL":"https:\/\/doi.org\/10.1186\/s13023-017-0733-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,8]]},"article-number":"2"}}